StreetInsider

• Log in to your account:

  
  Log in
• Signup
• Home
• EPS Insider
• Event Calendar
• Conferences
• Classic Site

Upgrade to SI Premium - Free Trial

Novartis (NVS)

Novartis reports kidney function benefits for IgAN drug in phase III trial June 4, 2026 6:16 AM - StreetInsider Novartis reports positive 144-week data for Scemblix in CML trial June 1, 2026 7:17 AM - StreetInsider China holds roundtable with over 50 foreign pharmaceutical firms May 22, 2026 9:54 AM - StreetInsider China Commerce Ministry holding meeting with foreign pharma companies including Lilly, Sanofi, Novartis, Merck May 22, 2026 9:24 AM - StreetInsider Novartis breaks ground on Texas radioligand therapy manufacturing site May 7, 2026 9:01 AM - StreetInsider Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities May 7, 2026 9:00 AM - Globe NewsWire Novartis receives Health Canada approval for Fabhalta® oral treatment for adults with C3G May 1, 2026 2:02 PM - StreetInsider Form 144 NOVARTIS AG Filed by: Bulto Carulla Victor April 30, 2026 12:06 PM - SEC Filing Novartis announces new API manufacturing facility in North Carolina April 30, 2026 7:04 AM - StreetInsider Novartis completes seventh US facility plan with North Carolina site April 30, 2026 7:01 AM - StreetInsider Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility April 30, 2026 7:00 AM - Globe NewsWire Form 6-K NOVARTIS AG For: Mar 31 April 28, 2026 6:22 AM - SEC Filing Novartis wins positive EU opinion for SMA gene therapy Itvisma April 24, 2026 6:31 AM - StreetInsider Novartis expands health programs to reach underserved communities globally April 9, 2026 3:55 AM - StreetInsider Novartis (NOVN:SW) (NVS) PT Raised to CHF135 at Kepler Cheuvreux April 2, 2026 5:49 AM - StreetInsider Novartis reports positive two-year results for Fabhalta in kidney disease March 30, 2026 4:18 AM - StreetInsider Novartis to acquire biotech Excellergy for up to $2 billion March 27, 2026 4:03 AM - StreetInsider Novartis to pay up to $2 billion for US biotech firm Excellergy March 27, 2026 2:29 AM - StreetInsider Novartis (NOVN:SW) (NVS) PT Raised to CHF135 at Morgan Stanley March 26, 2026 5:01 AM - StreetInsider Novartis (NVS) PT Raised to $170 at Morgan Stanley March 26, 2026 3:21 AM - StreetInsider Novartis to present immunology data at dermatology meeting March 23, 2026 4:52 AM - StreetInsider Novartis to acquire breast cancer drug developer for up to $3 billion March 20, 2026 8:21 AM - StreetInsider Form 6-K NOVARTIS AG For: Mar 18 March 18, 2026 4:24 PM - SEC Filing Form FWP NOVARTIS AG Filed by: NOVARTIS AG March 17, 2026 6:04 AM - SEC Filing Novartis (NOVN:SW) (NVS) PT Raised to CHF95 at HSBC March 17, 2026 3:42 AM - StreetInsider Novartis taps debt markets to fund $12 billion Avidity acquisition March 16, 2026 12:54 PM - StreetInsider Novartis gets FDA approval for Cosentyx in pediatric hidradenitis suppurativa March 13, 2026 1:37 PM - StreetInsider Argus Upgrades Novartis (NVS) to Buy March 11, 2026 7:34 AM - StreetInsider Increasing unusual call option volume: NVS BRBR BNO OMC QGEN SCO CGNX WEAT ZVRA March 11, 2026 4:37 AM - StreetInsider Novartis (NOVN:SW) (NVS) PT Raised to CHF110 at Berenberg March 9, 2026 2:44 AM - StreetInsider Full Article List